Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts
Overview
Authors
Affiliations
Mutations in the gene encoding collagen VII cause the devastating blistering disease recessive dystrophic epidermolysis bullosa (RDEB). RDEB is characterized by severe skin fragility and nonhealing wounds aggravated by scarring and fibrosis. We previously showed that TSP1 is increased in RDEB fibroblasts. Because transforming growth factor-β (TGF-β) signaling is also increased in RDEB, and TSP1 is known to activate TGF-β, we investigated the role of TSP1 in TGF-β signaling in RDEB patient cells. Knockdown of TSP1 reduced phosphorylation of smad3 (a downstream target of TGF-β signaling) in RDEB primary fibroblasts, whereas overexpression of collagen VII reduced phosphorylation of smad3. Furthermore, inhibition of TSP1 binding to the LAP/TGF-β complex decreased fibrosis in engineered extracellular matrix formed by RDEB fibroblasts, as evaluated by picrosirius red staining and analyses of birefringent collagen fibrillar deposits. We show that collagen VII binds TSP1, which could potentially limit TSP1-LAP association and subsequent TGF-β activation. Our study suggests a previously unreported mechanism for increased TGF-β signaling in the absence of collagen VII in RDEB patient skin. Moreover, these data identify TSP1 as a possible target for reducing fibrosis in the tumor-promoting dermal microenvironment of RDEB patients.
Nystrom A, Pattaroni C, Kern J JID Innov. 2025; 5(3):100353.
PMID: 40061239 PMC: 11889372. DOI: 10.1016/j.xjidi.2025.100353.
Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways.
Tang Q, Dong J, Zhang F, Zhao D, Yang Q, Wen J Front Pharmacol. 2025; 16:1489210.
PMID: 40017604 PMC: 11865199. DOI: 10.3389/fphar.2025.1489210.
Luszczynski K, Komorowski M, Soszynska M, Lewandowska P, Zdanowski R, Szafarowska M Int J Mol Sci. 2025; 26(1.
PMID: 39796089 PMC: 11720034. DOI: 10.3390/ijms26010233.
Aravena-Canales D, Valenzuela-Munoz V, Gallardo-Escarate C, Molina A, Valdes J Int J Mol Sci. 2024; 25(14).
PMID: 39062828 PMC: 11276852. DOI: 10.3390/ijms25147586.
Therapeutic targets of formononetin for treating prostate cancer at the single-cell level.
Li J, Huang Z, Wang P, Li R, Gao L, Lai K Aging (Albany NY). 2024; 16(12):10380-10401.
PMID: 38874510 PMC: 11236323. DOI: 10.18632/aging.205935.